Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the initiation of the global Phase 3 platinum resistant ovarian cancer (PROC) clinical trial in China for the development of Aravive’s batiraxcept.
Does Cybertruck Come In Black? Tesla Job Post Hints You May Get To Pick Some Colors
Elon Musk‘s Tesla Inc (NASDAQ:TSLA) is looking to hire a production supervisor for Cybertruck‘s paint shop in Texas. What Happened:…
